The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

Annals of Oncology

Volumn 20, Issue SUPPL.7, 2009, Pages 1-6

  Verslype, C ^a   Van Cutsem, E ^a   Dicato, M ^b   Arber, N ^c   Berlin, J D ^d   Cunningham, D ^e   De Gramont, A ^f   Diaz Rubio, E ^g   Ducreux, M ^h   Gruenberger, T ⁱ   Haller, D ^j   Haustermans, K ^a   Hoff, P ^k   Kerr, D ^l   Labianca, R ^m   Moore, M ⁿ   Nordlinger, B ^o   Ohtsu, A ^p   Rougier, P ^o   Scheithauer, W ⁱ   Schmoll, H J ^q   Sobrero, A ^r   Tabernero, J ^s   van de Velde, C ^t   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Luxembourg Medical Center   (Luxembourg)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f HÔPITAL SAINT ANTOINE   (France)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k HOSPITAL SÍRIO LIBANÊS   (Brazil)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m OSPEDALI RIUNITI   (Italy)

ⁿ UNIVERSITY OF TORONTO   (Canada)

^o HÔPITAL AMBROISE PARÉ   (France)

^p NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^q MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^r UNIVERSITY OF GENOA   (Italy)

^s HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^t LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chemoembolisation; Hepatocellular carcinoma; Liver transplantation; Sorafenib

Indexed keywords

CONFERENCE PAPER; CONSENSUS DEVELOPMENT; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 67449135811     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp281     Document Type: Conference Paper

References (36)

1. Goodman ZD, Terracciano LM. Tumours and tumour-like lesions of the liver. In Burt AD, Portmann BC, Ferrell LD (eds): MacSween's pathology of the liver, 5th edition. London: Churchill Livingstone 2007; 761-814.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
3. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142.
4. Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-748.
5. Van der Borght S, Libbrecht L, Katoonizadeh A et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007; 51: 855-856.
6. Lee JS, Chu IS, Heo J et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-676.
7. Durnez A, Verslype C, Nevens F et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-151.
8. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Eng J Med 1997; 336: 1855-1859.
9. Bruix J, Sherman M, Llovet JM. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
10. Bruix J, Sherman M. Practice Guidelines Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
11. Hussain SM, Zondervan PE, IJzermans JN et al. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 2002; 22: 1023-1036.
12. Lencioni R, Cioni D, Della Pina C et al. Imaging diagnosis. Semin Liver Dis 2005; 25: 162-170.
13. Gaiani S, Celli N, Piscaglia F et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41: 421-426.
14. Lencioni R, Della Pina C, Crocetti L et al. Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US. Eur Radiol 2007; 17(Supp l6): F73-F79.
15. Shimizu A, Ito K, Koike S et al. Cirrhosis or chronic hepatitis: evaluation of small (< or =2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003; 226: 550-555.
16. Libbrecht L, Bielen D, Verslype C et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8: 749-761.
17. Yu JS, Cho ES, Kim KH et al. Newly developed hepatocellular carcinoma (HCC) in chronic liver disease: MR imaging findings before the diagnosis of HCC. J Comput Assist Tomogr 2006; 30: 765-771.
18. Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Digest Liver Dis 2006; 38: 854-859.
19. Stigliano R, Marelli L, Yu D et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007; 33: 437-447.
20. CLIP group. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-5.
21. Collette S, Bonnetain F, Paoletti X et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 2008; 19: 1117-1126.
22. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
23. Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
24. Brunello F, Veltri A, Carucci P et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735.
25. Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909.
26. Mulier S, Ni Y, Jamart J et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242: 158-171.
27. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 14(334): 693-699.
28. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
29. Llovet JM, Real MI, Montaña X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
30. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5): 1164-1171.
31. Lencioni R, Malagari K, Vogl T et al. A randomised phase II trial of a drug eluting beads in the treatment of HCC by transcatheter arterial chemoembolisation (TACE) www.asco.org; GI Cancer Symposium 2009; abstract 116.
32. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
33. Nowak AK, Stockler MR, Chow PK, Findlay M. Use of tamoxifen in advancedstage hepatocellular carcinoma. A systematic review. Cancer 2005; 103: 1408-1414.
34. Kulik LM, Carr BI, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
35. Seong J, Lee IJ, Shim SJ et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009; 29: 147-152.
36. Lencioni R, Cioni D, Crocetti L et al. Magnetic resonance imaging of liver tumors. J Hepatol 2004; 40: 162-171.